Breast Cancer Genomics

Abstract

Breast cancer is a complex disease caused by the progressive accumulation of multiple gene mutations combined with epigenetic dysregulation of critical genes and protein pathways. There is substantial interindividual variability in both the age at diagnosis and phenotypic expression of the disease. With an estimated 1,152,161 new breast cancer cases diagnosed worldwide per year, cancer-control efforts in the post-genome era should be focused at both population and individual levels to develop novel risk assessment and treatment strategies that will further reduce the morbidity and mortality associated with the disease.The discovery that mutations in the BRCA1 and BRCA2 genes increase the risk of breast and ovarian cancers has radically transformed our understanding of the genetic basis of breast cancer, leading to improved management of high-risk women. A better understanding of tumor host biology has led to improvements in the multidisciplinary management of breast cancer, and traditional pathological evaluation is being complemented by more sophisticated genomic approaches. A number of genomic biomarkers have been developed for clinical use, and increasingly, pharmacogenetic end points are being incorporated into the clinical trial design.For women diagnosed with breast cancer, prognostic or predictive information is most useful when coupled with targeted therapeutic approaches, very few of which exist for women with triple-negative breast cancer or those with tumors resistant to chemotherapy. The immediate challenge is to learn how to use the molecular characteristics of an individual and their tumor to improve detection and treatment and, ultimately, to prevent the development of breast cancer.

Abstract 1987: Molecular characterization of the breast cancer-associated antigen NY-BR-1

“…Beside histone modification, DNA methylation (hypermethylation, hypomethylation, and loss of imprint) is crucial for making a gene accessible for transcription initiation and thus also plays an important role in tumour genesis (Kumar, 2014). In this process a methyl group is added to the 5-carbon position of cytosine (Widschwendter and Jones, 2002).…”